4-hydroxy-2-methoxy-N-methyl-benzamide | 1190090-24-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-hydroxy-2-methoxy-N-methyl-benzamide
• 英文别名: 4-Hydroxy-2-methoxy-N-methylbenzamide；4-hydroxy-2-methoxy-N-methylbenzamide
• CAS: 1190090-24-4
• 化学式: C₉H₁₁NO₃
• 分子量: 181.191
• InChiKey: DCYWEOZNBFBEOX-UHFFFAOYSA-N

物化性质

• 沸点：
  368.9±32.0 °C(Predicted)
• 密度：
  1.190±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-[(2R)-4-benzoyl-2-methyl-piperazin-1-yl]-2-bromo-propan-1-one 、 4-hydroxy-2-methoxy-N-methyl-benzamide 在 caesium carbonate 作用下， 以 丙酮 为溶剂， 反应 24.0h， 生成 4-[1-[(2R)-4-benzoyl-2-methylpiperazin-1-yl]-1-oxopropan-2-yl]oxy-2-methoxy-N-methylbenzamide
  参考文献：
  名称：

  Discovery of a small molecule inhibitor through interference with the gp120–CD4 interaction

  摘要：

  A series of piperazine derivatives were designed and synthesised as gp120-CD4 inhibitors. SAR studies led to the discovery of potent inhibitors in a cell based anti viral assay represented by compounds 9 and 28. The rat pharmacokinetic and antiviral profiles of selected compounds are also presented. Crown Copyright (C) 2009 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.06.080

文献信息

• [EN] NEW ANTIFIBRINOLYTIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS ANTIFIBRINOLYTIQUES
  申请人：PROYECTO BIOMEDICINA CIMA SL

  公开号：WO2014012964A1

  公开（公告）日：2014-01-23

  It relates to spirocyclic compounds of formula (I),or pharmaceutically or veterinary acceptable salts thereof, or any stereoisomers either of the compounds of formula (I) or of their pharmaceutically or veterinary acceptable salts, wherein A and B form a spirocyclic ring system wherein the spiro atom connecting A and B is a carbonatom and wherein A is a known 3- to 8-membered carbocyclic or heterocyclic monocyclic ring or a known 6- to 18-membered carbocyclic or heterocyclic polycyclic ring system; B is a known 4- to 7-membered carbocyclic or heterocyclic monocyclic ring; C is phenyl or a known 5- to 6-membered heteroaromatic ring; and R1-R7 are as defined herein. It also relates to a process for their preparation, as well as to the intermediates used in this process; to pharmaceutical or veterinary compositions containing them, and to their use in medicine, in particular as antifibrinolytic and antihemorragic agents.

  这涉及到公式(I)的螺环化合物，或其在药用或兽医学上可接受的盐，或者公式(I)化合物或其药用或兽医学上可接受的盐的立体异构体，其中A和B形成一个螺环系统，其中连接A和B的螺原子是一个碳原子，A是已知的3-至8-成员碳环或杂环单环，或已知的6-至18-成员碳环或杂环多环系统；B是已知的4-至7-成员碳环或杂环单环；C是苯基或已知的5-至6-成员杂芳环；R1-R7如此定义。它还涉及到它们的制备方法，以及在该过程中使用的中间体；含有它们的药用或兽医学组合物，以及它们在医学中的用途，特别是作为抗纤溶和抗出血剂。
• NEW ANTIFIBRINOLYTIC COMPOUNDS
  申请人：PROYECTO DE BIOMEDICINA CIMA, S.L.

  公开号：US20150175618A1

  公开（公告）日：2015-06-25

  It relates to spirocyclic compounds of formula (I), or pharmaceutically or veterinary acceptable salts thereof, or any stereoisomers either of the compounds of formula (I) or of their pharmaceutically or veterinary acceptable salts, wherein A and B form a spirocyclic ring system wherein the spiro atom connecting A and B is a carbon atom and wherein A is a known 3- to 8-membered carbocyclic or heterocyclic monocyclic ring or a known 6- to 18-membered carbocyclic or heterocyclic polycyclic ring system; B is a known 4- to 7-membered carbocyclic or heterocyclic monocyclic ring; C is phenyl or a known 5- to 6-membered heteroaromatic ring; and R 1 -R 7 are as defined herein. It also relates to a process for their preparation, as well as to the intermediates used in this process; to pharmaceutical or veterinary compositions containing them, and to their use in medicine, in particular as antifibrinolytic and antihemorragic agents.

  本发明涉及公式(I)的螺环化合物，或其药学或兽医可接受的盐，或任何化合物的立体异构体(I)或其药学或兽医可接受的盐，其中A和B形成一个螺环系统，其中连接A和B的螺原子是一个碳原子，其中A是已知的3-8个成员的碳环或杂环单环或已知的6-18个成员的碳环或杂环多环系统；B是已知的4-7个成员的碳环或杂环单环；C是苯或已知的5-6个成员的杂芳环；R1-R7如本文所定义。本发明还涉及制备它们的方法，以及用于该过程中使用的中间体；包含它们的药学或兽医组合物，并将其用于医学，特别是作为抗纤溶和抗出血剂。
• TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS
  申请人：Omeros Corporation

  公开号：EP2846805A2

  公开（公告）日：2015-03-18
• US9440989B2
  申请人：——

  公开号：US9440989B2

  公开（公告）日：2016-09-13
• [EN] TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS<br/>[FR] TRAITEMENT DE LA DÉPENDANCE ET DES TROUBLES DU CONTRÔLE DES IMPULSIONS À L'AIDE D'INHIBITEURS DE PDE7
  申请人：OMEROS CORP

  公开号：WO2013176877A2

  公开（公告）日：2013-11-28

  This disclosure is directed to treatment of addictions and primary impulse- control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.